Karpenko O. Genetic aspects of the activity of the hemocoagulation system and the effectiveness of antithrombotic treatment in patients with ischemic heart disease associated with type 2 diabetes

The dissertation proposes a comprehensive application of hemostasiological analysis of platelet and plasma units and molecular genetic analysis of the selected system of candidate genes for a personalized approach to diagnosis and treatment of patients with various forms of ischemic heart disease and in combination with type 2 diabetes mellitus. Aim: to establish the features of changes in platelet and plasma hemostasis in patients with coronary heart disease with concomitant type 2 diabetes mellitus, depending on G20210A polymorphism of the FII gene, G455A polymorphism of the FGB gene, T1565C polymorphism of the ITGB3 gene, G681A polymorphism of the CYP2C19 gene and antithrombotic treatment. The aim of the study is relevant due to the high prevalence of this comorbid pathology among the Ukrainian population and based on the many complications that develop against the background of the combined course of the disease, there is a need for intensive study of diagnostic indicators of one of the most involved links - hemostasis systems. Knowledge of genetic factors that contribute to the development of the disease and its complications can be of important prognostic value and used in the selection of drugs and treatments. Objectives of the study: 1. To establish the features of changes in platelet and plasma hemostasis in patients with coronary heart disease with concomitant diabetes mellitus. 2. To study the types of G20210A polymorphism of the FII gene, G455A polymorphism of the FGB gene, T1565C polymorphism of the ITGB3 gene, G681A polymorphism of the CYP2C19 gene and to analyze their prevalence in different forms of coronary heart disease. 3. To investigate the activity of platelet hemostasis and determine the influence of G20210A polymorphism of the FII gene, G455A polymorphism of the FGB gene, T1565C polymorphism of the ITGB3 gene, on spontaneous and induced platelet aggregation activity. 4. Determine the state of blood coagulation activity depending on the G20210A polymorphism of the FII gene, G455A polymorphism of the FGB gene, T1565C polymorphism of the ITGB3 gene. 5. To establish the sensitivity to clopidogrel in genotypes of G681A polymorphism of the CYP2C19 gene based on a comprehensive assessment of platelet hemostasis.